JP2025172140A5 - - Google Patents
Info
- Publication number
- JP2025172140A5 JP2025172140A5 JP2025145434A JP2025145434A JP2025172140A5 JP 2025172140 A5 JP2025172140 A5 JP 2025172140A5 JP 2025145434 A JP2025145434 A JP 2025145434A JP 2025145434 A JP2025145434 A JP 2025145434A JP 2025172140 A5 JP2025172140 A5 JP 2025172140A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- composition according
- peptide
- terminus
- modification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862748711P | 2018-10-22 | 2018-10-22 | |
| US62/748,711 | 2018-10-22 | ||
| JP2021521472A JP7426121B2 (ja) | 2018-10-22 | 2019-10-18 | Cxcr3の切断可能な活性化因子および使用方法 |
| PCT/US2019/056955 WO2020086400A1 (en) | 2018-10-22 | 2019-10-18 | Cleavable activators of cxcr3 and methods of use |
| JP2023198254A JP7798368B2 (ja) | 2018-10-22 | 2023-11-22 | Cxcr3の切断可能な活性化因子および使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023198254A Division JP7798368B2 (ja) | 2018-10-22 | 2023-11-22 | Cxcr3の切断可能な活性化因子および使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025172140A JP2025172140A (ja) | 2025-11-20 |
| JP2025172140A5 true JP2025172140A5 (cg-RX-API-DMAC7.html) | 2026-03-30 |
Family
ID=70330587
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021521472A Active JP7426121B2 (ja) | 2018-10-22 | 2019-10-18 | Cxcr3の切断可能な活性化因子および使用方法 |
| JP2023198254A Active JP7798368B2 (ja) | 2018-10-22 | 2023-11-22 | Cxcr3の切断可能な活性化因子および使用方法 |
| JP2025145434A Pending JP2025172140A (ja) | 2018-10-22 | 2025-09-02 | Cxcr3の切断可能な活性化因子および使用方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021521472A Active JP7426121B2 (ja) | 2018-10-22 | 2019-10-18 | Cxcr3の切断可能な活性化因子および使用方法 |
| JP2023198254A Active JP7798368B2 (ja) | 2018-10-22 | 2023-11-22 | Cxcr3の切断可能な活性化因子および使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12110316B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3870212A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7426121B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102984527B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN113038965B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2019365654B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021007414A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3116325A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL282431B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021004496A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202103497WA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020086400A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202103497WA (en) * | 2018-10-22 | 2021-05-28 | Univ Pittsburgh Commonwealth Sys Higher Education | Cleavable activators of cxcr3 and methods of use |
| GB202208950D0 (en) * | 2022-06-17 | 2022-08-10 | Ucl Business Ltd | Treatment of the corneal endothelium |
| US20260201006A1 (en) * | 2022-11-30 | 2026-07-16 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Coacervate formulations of cxcr-activating peptides for controlled release in ophthalmic and topical treatments |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994292A (en) | 1995-05-31 | 1999-11-30 | The United States Of America As Represented By The Department Of Health And Human Services | Interferon-inducible protein 10 is a potent inhibitor of angiogenesis |
| MXPA00003885A (es) * | 1997-10-22 | 2004-04-23 | Inst Genetics Llc | Quimiocinas con modificiaciones de la terminacion amino. |
| US20070116669A1 (en) | 2002-09-13 | 2007-05-24 | Chemokine Therapeutics Corporation | Interferon-inducible protein-10 (IP-10 or CXCL10) chemokine analogs for the treatment of human diseases |
| GB2377444A (en) | 2001-04-09 | 2003-01-15 | Smithkline Beecham Plc | Chemokine-family polypeptide |
| CA2525647A1 (en) * | 2003-05-16 | 2005-02-24 | Intermune, Inc. | Synthetic chemokine receptor ligands and methods of use thereof |
| IL164942A0 (en) * | 2004-10-31 | 2005-12-18 | Yeda Res & Dev | The use of a protease or a protease inhibitor for the manufacture of medicaments |
| WO2013032853A1 (en) | 2011-08-26 | 2013-03-07 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Activators of cxcr3 for the treatment of angiopathies of the eye |
| US8734775B2 (en) | 2011-08-26 | 2014-05-27 | University Of Pittsburgh | Chemokine derived peptides that bind with chemokine receptor CXCR3 and uses for chronic wound and angiogenesis inhibition treatments |
| WO2015021058A2 (en) * | 2013-08-05 | 2015-02-12 | Greenlight Biosciences, Inc. | Engineered proteins with a protease cleavage site |
| EP3096777B1 (en) * | 2014-01-21 | 2021-01-20 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Goblet cell replacement therapy |
| EA035259B1 (ru) * | 2014-02-14 | 2020-05-21 | Иммьюн Дизайн Корп. | Иммунотерапия рака с применением комбинации местной и системной иммунной стимуляции |
| EP3478321A4 (en) * | 2016-06-30 | 2020-04-22 | Oncorus, Inc. | PSEUDOTYPIZED ONCOLYTIC VIRAL ADMINISTRATION OF THERAPEUTIC POLYPEPTIDES |
| AU2017364818C1 (en) * | 2016-11-28 | 2025-05-15 | Chugai Seiyaku Kabushiki Kaisha | Ligand-binding molecule having adjustable ligand binding activity |
| MY200973A (en) | 2017-04-11 | 2024-01-26 | Inhibrx Inc | Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same |
| SG11202103497WA (en) | 2018-10-22 | 2021-05-28 | Univ Pittsburgh Commonwealth Sys Higher Education | Cleavable activators of cxcr3 and methods of use |
-
2019
- 2019-10-18 SG SG11202103497WA patent/SG11202103497WA/en unknown
- 2019-10-18 KR KR1020217014758A patent/KR102984527B1/ko active Active
- 2019-10-18 IL IL282431A patent/IL282431B2/en unknown
- 2019-10-18 JP JP2021521472A patent/JP7426121B2/ja active Active
- 2019-10-18 CA CA3116325A patent/CA3116325A1/en active Pending
- 2019-10-18 CN CN201980069480.8A patent/CN113038965B/zh active Active
- 2019-10-18 WO PCT/US2019/056955 patent/WO2020086400A1/en not_active Ceased
- 2019-10-18 EP EP19875282.6A patent/EP3870212A4/en active Pending
- 2019-10-18 AU AU2019365654A patent/AU2019365654B2/en active Active
- 2019-10-18 MX MX2021004496A patent/MX2021004496A/es unknown
- 2019-10-18 CN CN202510050400.1A patent/CN120022352A/zh active Pending
- 2019-10-18 BR BR112021007414-7A patent/BR112021007414A2/pt unknown
- 2019-10-18 KR KR1020267020485A patent/KR20260109974A/ko active Pending
- 2019-10-18 US US17/287,480 patent/US12110316B2/en active Active
- 2019-10-18 IL IL324815A patent/IL324815A/en unknown
-
2023
- 2023-11-22 JP JP2023198254A patent/JP7798368B2/ja active Active
-
2024
- 2024-08-28 US US18/817,667 patent/US20250002549A1/en active Pending
-
2025
- 2025-02-08 AU AU2025200880A patent/AU2025200880B2/en active Active
- 2025-09-02 JP JP2025145434A patent/JP2025172140A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7083983B2 (en) | Inhibitors of the interaction between P53 and MDM2 | |
| CA1339623C (en) | Lhrh antagonists | |
| US20050090448A1 (en) | Peptides that inhibit complement activation | |
| CN101265299A (zh) | 来自杀菌性通透性增强蛋白的功能区的生物活性肽及其应用 | |
| US9777051B2 (en) | TFPI inhibitors and methods of use | |
| CN105451755A (zh) | 铁调素类似物和其用途 | |
| JPH09507501A (ja) | 殺菌性/透過性が向上したタンパク質の機能領域に由来する生物学的に活性なペプチドおよびその使用 | |
| RU2007110981A (ru) | Урокортин iii и его использование | |
| JP2011518179A5 (cg-RX-API-DMAC7.html) | ||
| EP3131925B1 (en) | Modified relaxin b chain peptides | |
| CN101273059A (zh) | 治疗活性的α-MSH类似物 | |
| JP2023116739A5 (cg-RX-API-DMAC7.html) | ||
| JP2022512770A5 (cg-RX-API-DMAC7.html) | ||
| US7244701B2 (en) | Diuretic peptide conjugate | |
| WO2022125606A2 (en) | Peptide therapeutics for treating alzheimer's disease and related conditions | |
| KR20250042844A (ko) | 결장 세정을 위한 조성물 및 위장 장애의 치료 | |
| JP4812347B2 (ja) | 抗菌性ペプチド | |
| CN101808655B (zh) | 衍生自纤溶酶原激活物抑制剂-1的肽和其应用 | |
| Zikos et al. | Comparative evaluation of four trityl‐type amidomethyl polystyrene resins in Fmoc solid phase peptide synthesis | |
| CN100413883C (zh) | 选择性地与p-选择蛋白结合的肽化合物 | |
| JP2009509552A (ja) | 先天免疫を調節することによる感染の処置および予防を含む、免疫関連疾患障害の処置および予防のための新規ペプチド | |
| US6964948B2 (en) | Therapeutic peptide-based constructs derived from Domain II of bactericidal/permeability-increasing protein | |
| Sakura et al. | Structure-activity relationships of neuromedin U. IV. Absolute requirement of the arginine residue at position 7 of dog neuromedin U-8 for contractile activity | |
| WO2005119266A1 (en) | Sr-a antagonists | |
| EP1337551B1 (en) | Substance p analogs for the treatment of cancer |